Last reviewed · How we verify
Dry plasma
Dry plasma is a lyophilized (freeze-dried) blood plasma product that restores coagulation factors and other plasma proteins when reconstituted.
Dry plasma is a lyophilized (freeze-dried) blood plasma product that restores coagulation factors and other plasma proteins when reconstituted. Used for Acute bleeding and coagulation factor deficiency, Perioperative hemostasis support, Massive transfusion protocols.
At a glance
| Generic name | Dry plasma |
|---|---|
| Sponsor | Vastra Gotaland Region |
| Drug class | Blood product / Plasma derivative |
| Modality | Biologic |
| Therapeutic area | Hematology / Hemostasis |
| Phase | FDA-approved |
Mechanism of action
Dry plasma is prepared by freeze-drying fresh frozen plasma to create a stable, shelf-stable product. When reconstituted with sterile water, it provides multiple coagulation factors (II, V, VII, IX, X, XI, XII), fibrinogen, and other plasma proteins needed for hemostasis. It is used as a hemostatic agent in acute bleeding situations where rapid coagulation factor replacement is needed.
Approved indications
- Acute bleeding and coagulation factor deficiency
- Perioperative hemostasis support
- Massive transfusion protocols
Common side effects
- Transfusion-related acute lung injury (TRALI)
- Allergic reactions
- Thromboembolic events
- Infection transmission risk
Key clinical trials
- The ILERVAS Project: Assessing the Prevalence of Subclinical Vascular Disease and Hidden Kidney Disease (NA)
- Analysis of Inflammatory Biomarker Changes in Dry Blood Spot Versus Venous Blood Samples
- Effects of Bilberry and Oat Intake After Type 2 Diabetes and/or MI (NA)
- Study in Leptomeningeal Metastases of Breast Cancer (NA)
- Subtenon PRP Injection for Geographic Atrophy in Dry Age-Related Macular Degeneration (NA)
- Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Age (PHASE3)
- A Study of the Pharmacokinetics and Safety of Single-dose Inhaled RJ026 in Healthy Volunteers and Patients With Interstitial Lung Disease (PHASE1)
- Immune Response and Risk of Serious Infection to SARS-Cov2
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dry plasma CI brief — competitive landscape report
- Dry plasma updates RSS · CI watch RSS
- Vastra Gotaland Region portfolio CI